PSA Screening in 2023

Gerald L. Andriole, Jr., MD, Director of Urology in the National Capital Region at the Brady Urologic Institute at Johns Hopkins University, reviews evidence supporting a more comprehensive family history and biomarkers in screening and treating prostate cancer. He provides his insights on identifying patients with clinically significant PCa earlier, reducing unnecessary initial and repeat prostate biopsies.

[seascape]

My husband, 71 y.o., PSA of 6.5, negative DRE, avoided biopsy because of a 1% score on 4K test, and favorable free PSA to bound PSA ratio. It seems like many urologists are still oriented to random biopsy once PSA exceeds 4.0 .